Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

60 results about "Body cells" patented technology

Definition of body cell. 1: somatic cell-opposed to germ cell. 2: the one of two cells produced by division of the generative cell in the pollen grain of certain gymnosperms that in turn divides to produce two male nuclei or cells.

Hypoglycemic health-care product rich in bitter gourd polypeptide and application of hypoglycemic health-care product

The invention relates to the technical field of health-care products, in particular to a health-care product rich in momordica charantia polypeptide and capable of regulating blood sugar metabolism and promoting insulin secretion, momordica charantia polypeptide can stimulate pancreatic beta cells to secrete insulin, and insulin is the only hormone capable of reducing blood sugar in a human body. The balsam pear polypeptide component in the balsam pear extract is specially used for reducing the blood sugar level and improving related health problems, the application of the balsam pear polypeptide in the health care product can effectively regulate the blood sugar metabolism of a human body and promote the secretion of insulin, and the balsam pear polypeptide stimulates pancreas islet beta cells to promote the secretion of insulin. In addition, the balsam pear polypeptide can improve the insulin resistance, increase the number of insulin receptors or enhance the activity of the insulin receptors, so that the body cells are more sensitive to the insulin, the uptake and utilization of glucose are promoted, and the abnormal increase of the blood glucose level is avoided.
Owner:YUKANG PHARMACEUTICAL (GUANGZHOU) CO LTD

Method for cultivating triploid kelp sporophyte and identifying ploidy of induced protonema

The invention discloses a method for cultivating triploid kelp sporophytes and identifying ploidy of induced protonema, and belongs to the field of kelp breeding. The method is based on a capillary glass needle separation technology for inducing filamentous somatic cells by kelp and a molecular biological technology for specific marking of sex of kelp gametophytes. The sex specific marker of the kelp gametophyte is used for carrying out PCR (Polymerase Chain Reaction) amplification and 1.5% agarose gel electrophoresis detection on the separated induction protonema single-cell cloning line, so that the genetic sex of the kelp induction protonema can be accurately identified; and the ploidy of the induced protonema of a part of varieties (lines) is directly determined from the molecular level. The method for synchronously detecting the genetic sex and ploidy of the induced protonema breaks through the bottlenecks of chromosome counting and flow cytometry operation, can be completed only through one-time PCR amplification, and is simple, convenient, rapid, short in time consumption, capable of completing detection of a plurality of samples at the same time and low in cost.
Owner:SHANDONG ORIENTAL OCEAN SCI TECH

A method for separating, identifying and adipogenically differentiating mammalian adipocyte precursor cells, a composition and application thereof

The present invention belongs to the technical field of in vitro cell differentiation. The present invention provides a method, composition and application for separation, identification and adipogenic differentiation of mammalian adipocytes. The mechanical method combined with collagenase digestion method is used to successfully separate and obtain mammalian adipocytes. Immunofluorescence technology is used to identify the obtained adipocytes. The adipogenic differentiation method of adipocytes is explored by a combination of multiple adipogenic induction factors. The differentiated mature adipocytes are identified by Oil Red O staining, BODIPY staining, triglyceride (TAG) content determination and / or Western blot technology. The results show that the adipogenic differentiation method of the present invention has good beneficial effects, is an ideal method for studying adipocyte differentiation, and has important application value in the fields of animal husbandry, biomedicine and biological meat cultivation.
Owner:CHINA MEAT RES CENT

Single-chain donanemab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of donanemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain natalizumab antibody-transferrin fusion protein for enhanced efficacy and indications

PendingUS20260049147A1Hybrid immunoglobulinsTransferrinsNatalizumab AntibodyExocytosis
The efficacy and indication of natalizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single chain adalimumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of adalimumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors
Owner:RNA THERAPEUTICS INC

Single-chain ranibizumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of ranibizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain alemtuzumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of ALEMTUZUMAB do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain MEDI1341 antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of MEDI1341 do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Application of sulfated polysaccharides in resisting novel coronavirus

The disclosure provides application of sulfated polysaccharides in resisting novel coronavirus, belonging to the technical field of biomedicine. It is confirmed in the disclosure that by binding to an S protein on the surface of the SARS-CoV-2 virus, the sea cucumber polysaccharides, fucoidans or carrageenans can prevent cell membranes of body cells from adsorbing and internalizing the SARS-CoV-2 virus, thereby preventing the SARS-CoV-2 virus from infecting the body cells, which indicates that the sea cucumber polysaccharides, fucoidans or carrageenans have the effect of prevention and treatment of pneumonia caused by the novel coronavirus. These polysaccharides can be used to prepare protective articles having functions of prevention and treatment of novel coronavirus infection, for example: inhalations, hand lotions, oral liquids and respirators.
Owner:DALIAN POLYTECHNIC UNIVERSITY

Single-chain dupilumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of dupilumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Application of PHD3 inhibitor in prevention and treatment of AIDS

The invention discloses an application of a PHD3 inhibitor in prevention and treatment of AIDS (acquired immune deficiency syndrome). Through multidisciplinary research means of immunology, biochemistry and the like, the situation that virus antisense protein ASP inhibits generation of I-type IFN in the HIV-1 infection process is analyzed, immune escape is achieved, and a latent infection mechanism is established. In the aspect of mechanism, the ASP can play the inhibiting role after transcriptional expression into protein in a body cell through post-translational modification, the 47-site proline of the ASP can be helped to realize the capability of inhibiting the immune response of the body after hydroxylation modification, and the post-translational modification is realized by depending on proline hydroxylase 3 (PHD3) of a host. On the basis of mechanism research, it is found that a PHD3 inhibitor Molidustat counteracts hydroxylation of PHD3 to ASP, so that immune escape of HIV-1 is blocked, infection is antagonized, and good development prospects of AIDS treatment and prevention drugs are shown.
Owner:SHANGHAI PUBLIC HEALTH CLINICAL CENT

Single-chain solanezumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of solanezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain prasinezumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of prasinezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain semorinemab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of semorinemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain cetuximab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of cetuximab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Hybrid light chain mouse

To provide a hybrid light chain mouse.SOLUTION: There is provided a mouse genetically modified to appear a Homo sapiens λ variable (hVλ) sequence (containing a mouse for appearing the hVλ sequence from an endogenous mouse λ light chain gene locus, a mouse for appearing an hVλ sequence from an endogenous mouse κ light chain gene locus, and a mouse for appearing hVλ sequence from a transducing gene or an episome). Here, the hVλ sequence is connected to a mouse steady sequence. There is provided a mouse for becoming an origin of the Homo sapiens λ variable sequence which has been varied into a body cell variation useful for preparing an antigen binding protein. There are provided a composition and a method for preparing an antigen binding protein containing a human λ variable sequence containing a human antibody.SELECTED DRAWING: Figure 7B
Owner:REGENERON PHARMACEUTICALS INC

Single-chain tildrakizumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of tildrakizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Method and device for inducing pluripotent stem cells

PendingCN121495830ACulture processArtificial cell constructsStem cell productReprogramming
The invention discloses a method and device for inducing pluripotent stem cells, and relates to the technical field of cell culture.The inducing method specifically comprises the following steps that S1, target cells are separated and treated and inoculated into a three-dimensional support containing a culture medium, and meanwhile a space gradient microenvironment is established; s2, performing periodic physical stimulation on each target body cell by adopting low-intensity pulse ultrasound, and activating a signal channel corresponding to mechanical transduction in cooperation with a small molecule inducer; s3, adding a photosensitive metabolism intermediate precursor or a photoresponsive regulating agent into the three-dimensional bracket, and performing time-limited irradiation; by simulating a signal environment of embryonic development, directional migration and gradual reprogramming of each target body cell are effectively guided, accurate intervention on different target body cells is realized, meanwhile, a reprogramming effect is verified from multiple angles, and the quality and stability of a pluripotent stem cell product are guaranteed.
Owner:LANGZISEL BIOTECHNOLOGY (XIANYANG) CO LTD

Single-chain gantenerumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of gantenerumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

A gene-regulation-based tumor stem cell inhibiting drug and preparation method thereof

The application discloses a tumor stem cell inhibiting medicine based on gene regulation and a preparation method thereof, and belongs to the technical field of biological medicines. The medicine takes a targeted interference fragment of a tumor stem cell specific regulation gene TSC-G as a core active component, and is composed of only the targeted interference fragment and a modified liposome. The modified liposome is composed of DSPC, Chol and PEG-DSPE in a specific ratio, and has high targeting property and good stability. The preparation method comprises four steps of targeted interference fragment synthesis, modified liposome preparation, medicine assembly and purification, and has simple process and high purity. The medicine can effectively inhibit self-renewal, proliferation and differentiation of tumor stem cells, the tumor stem cell inhibition rate is greater than or equal to 88%, the tumor volume inhibition rate in vivo is greater than or equal to 78%, the medicine has no toxicity to normal body cells, the technical scheme is unique, the medicine can be used for clinical tumor treatment, and the problem of tumor recurrence and drug resistance can be solved from the root.
Owner:CLAYYURE GENE TECH CO LTD

Single-chain eculizumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of eculizumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Covered endoprosthesis with improved branch access

An endoprosthesis may include an expandable framework including an anchoring portion and a body portion extending axially from the anchoring portion, the body portion having a plurality of body cells; and a polymeric cover disposed on at least a portion of the expandable framework. The anchoring portion includes a first transverse flange and a second transverse flange proximate the first transverse flange, the first and second transverse flanges being configured to secure the anchoring portion at an orifice of a body lumen. The body portion includes a window through a side of the body portion, the window occupying space equivalent to at least two of the plurality of body cells. The window is devoid of the polymeric cover and any other structure within a perimeter of the window.
Owner:BOSTON SCIENTIFIC SCIMED INC

Single-chain belimumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of belimumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors
Owner:RNA THERAPEUTICS INC

Single-chain infliximab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of infliximab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain ustekinumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of ustekinumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

A filter membrane and method for extracting DNA from evidence specimens

ActiveCN115820623BDNA preparationMagnetic beadAllotype
The present invention discloses a filter membrane and a method for extracting DNA from physical evidence samples, comprising the following steps: S1: soaking the filter membrane with a first magnetic bead suspension, filtering the first magnetic bead suspension soaked with the filter membrane until the liquid on the filter membrane is drained, thereby obtaining a filter membrane adsorbed with magnetic beads; S2: flushing the surface of the physical evidence sample with a mixture of a buffer solution and a second magnetic bead suspension to obtain an enriched liquid, filtering the enriched liquid with the filter membrane adsorbed with magnetic beads until the enriched liquid on the filter membrane is drained, thereby obtaining a filter membrane enriched with DNA and / or body cells; S3: extracting DNA from the filter membrane enriched with DNA and / or body cells. The present invention solves the problem that existing extraction methods cannot accurately extract DNA from physical evidence samples that are large in size, have good water resistance, are irregular in shape, have few detached cells, and are scattered, thereby achieving the purpose of accurately extracting trace DNA from multi-type, multi-morphological, and irregular physical evidence samples.
Owner:ZHUHAI XIANGZHEN BIOTECHNOLOGY CO LTD +1

Single-chain trastuzumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of trastuzumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain lecanemab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of lecanemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC

Single-chain canakinumab antibody-transferrin fusion protein for enhanced efficacy and indications

The efficacy and indication of canakinumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Owner:RNA THERAPEUTICS INC